HLA-B27-FITC/HLA-B7-PE Antibody Cocktail

A07739


This mixture permits the characterization of HLA-B27 specificity in the HLA class I allotype in patients suffering from inflammatory disorders affecting the sacroiliac and intervertebral joints.

This finding aids in the diagnosis of ankylosing spondylitis 90% of sufferers of which express the HLA-B27 antigen, versus 7% in the normal population.

The HLA-ABC-m3 monoclonal antibody recognizes the HLA-B27 antigen. It crosses with the HLA-B7 antigen and can also become fixed, but in a less refined manner, to the other antigens of CREG HLA-B7. The BB7.1 monoclonal antibody recognizes the HLA-B7 antigen.

Specifications

Target Species Human
Specificity HLA-B27, HLA-B7
Fluorochrome FITC, PE
Regulatory Status CE
Size 50 Tests
Format Liquid
Flow Product Line IOTest
Clone HLA-ABC-m3 / BB7.1

Technical Documents

NOT ALL PRODUCTS ARE AVAILABLE IN ALL COUNTRIES
PRODUCT AVAILABILITY AND REGULATORY STATUS DEPENDS ON COUNTRY REGISTRATION PER APPLICABLE REGULATIONS

The listed regulatory status for products correspond to one of the below:
IVD: In Vitro Diagnostic Products. These products are labeled "For In Vitro Diagnostic Use."
ASR: Analyte Specific Reagents. These reagents are labeled "Analyte Specific Reagents. Analytical and performance characteristics are not established."
CE: Products intended for in vitro diagnostic use and conforming to European Directive (98/79/EC). (Note: Devices may be CE marked to other directives than (98/79/EC)
RUO: Research Use Only. These products are labeled "For Research Use Only. Not for use in diagnostic procedures."
LUO: Laboratory Use Only. These products are labeled "For Laboratory Use Only."
No Regulatory Status: Non-Medical Device or non-regulated articles. Not for use in diagnostic or therapeutic procedures.